Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
Novartis earnings, tech stocks maintain STOXX 600's record winning streak
By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
FiercePharma11h
Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
BioSpace13h
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
Novartis delays Phase 3 readout for Ionis heart drug
Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...